<DOC>
	<DOCNO>NCT01866306</DOCNO>
	<brief_summary>The purpose study establish safety tolerability Unbiased Biomarkers Prediction Respiratory Disease Outcomes ( U-BIOPRED ) human rhinovirus 16 ( RV16UB ) healthy asthmatic participant , identify appropriate dosage RV16UB order study biomarkers asthmatic participant . The study divide 2 part . Part 1 dose-finding study healthy participant , asthmatic participant , either treat treated class long-acting beta antagonist ( LABA ) recruit undergo nasal challenge increase dos RV16UB . Part 2 biomarker study mild moderate asthmatic undergo challenge appropriate dose RV16UB identify Part 1 , base tolerability viral effect . .</brief_summary>
	<brief_title>A Study Evaluate Safety Use Human Rhinovirus Healthy Asthmatic Participants ( MK-0000-218 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Parts 1 2 : Body Mass Index ( BMI ) = &lt; 35 kg/m^2 &gt; 17 kg/m^2 female childbearing potential pregnant agrees use 2 acceptable method birth control 10 day last visit , ; female nonchildbearing potential nonsmoker , smoke within prior 12 month , history = &lt; 10 packyears Part 1 : Either follow : healthy ( may outof season seasonal allergy ) mild moderateasthmatic history spontaneous exertional wheezing ; follow &gt; 4 week prior : daytime symptom twice weekly less , activity limitation , nocturnal symptom , use reliever treatment twice daily less , unchanged asthma medication dose , use inhale corticosteroid ( ICS ) stable doseequivalent = &lt; 500 mcg/day fluticasone propionate Part 2 : mild moderateasthmatics history spontaneous exertional wheezing ; follow &gt; 4 week prior : daytime symptom twice weekly less , activity limitation , nocturnal symptom , use reliever treatment twice daily less , unchanged asthma medication dose , use ICS stable doseequivalent = &lt; 500 mcg/day fluticasone propionate mild change symptom associated viral syndrome , lead temporarily increase short act beta agonist use increase ICS dose within past 5 year history severe difficult manage allergy ( e.g . food , drug , latex ) history asthmarelated ventilatory failure adolescence adulthood positive hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus ( HIV ) significant nasal septum deviation , nasal polyp nasal anatomical abnormality share household intimate contact infant , pregnant lactate woman , immunosuppressed individual history current evidence upper low respiratory tract infection within 6 week prior baseline assessment major surgery lose 1 unit ( 500 mL ) blood within prior 4 week participate another investigational trial within prior 10 week pregnant nursing mother use exclude prescription nonprescription medication within 2 week prior initial viral challenge throughout trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>